The impact of the Canada – United States – Mexico Agreement on prescription drug expenditures in Canada

This report estimates the additional pharmacy-dispensed prescription drug expenditures for Canadian consumers that would result from the Canada-United States-Mexico Agreement (CUSMA). A two-year extension of data protection for biologics will delay the introduction of biosimilars for some expensive drugs. This would likely keep prices higher than they otherwise would have been.